TOPICAL: Randomized phase III trial of erlotinib compared with placebo in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and …

S Lee, R Rudd, I Khan, S Upadhyay… - Journal of Clinical …, 2010 - ascopubs.org
7504 Background: Poor performance status (PS) NSCLC is an important, under-studied
group of lung cancer patients, affecting 30-40% of patients. We determined the role of …
被引用次数：49 相关文章

[引用][C] TOPICAL: Randomized phase III trial of erlotinib compared with placebo in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) …

S Lee, R Rudd, I Khan, S Upadhyay… - Journal of Clinical …, 2010 - cir.nii.ac.jp
TOPICAL: Randomized phase III trial of erlotinib compared with placebo in chemotherapy-naive
patients with advanced non-small cell lung cancer (NSCLC) and unsuitable for first-line …